Equities Analysts Set Expectations for DNLI Q3 Earnings

Key Points

• HC Wainwright raised Denali Therapeutics’ Q3 2026 loss estimate to $0.67 per share from $0.68, while projecting the company will reach approximately breakeven in fiscal 2030.
• Denali’s latest quarterly results missed expectations, with a loss of $0.68 per share versus the $0.51 consensus estimate, although revenue of $3.60 million exceeded the $2.15 million forecast.
• Analyst sentiment remains favorable, with 13 Buy ratings, two Holds and one Sell; the stock carries a “Moderate Buy” consensus rating and a $35.92 average price target versus its recent $25.00 share price.

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Equities research analysts at HC Wainwright lifted their Q3 2026 earnings per share estimates for Denali Therapeutics in a research note issued to investors on Friday, August 7th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($0.67) per share for the quarter, up from their previous estimate of ($0.68). The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.73) per share. HC Wainwright also issued estimates for Denali Therapeutics' FY2026 earnings at ($2.70) EPS, FY2027 earnings at ($2.54) EPS, FY2028 earnings at ($2.46) EPS, FY2029 earnings at ($1.35) EPS and FY2030 earnings at $0.01 EPS.

A number of other equities research analysts have also weighed in on DNLI. Wedbush reaffirmed an "outperform" rating and set a $26.00 target price on shares of Denali Therapeutics in a research note on Monday, July 13th. Robert W. Baird set a $34.00 price target on shares of Denali Therapeutics in a research note on Friday. Stifel Nicolaus set a $41.00 price objective on shares of Denali Therapeutics in a report on Monday, June 22nd. Sanford C. Bernstein reaffirmed a "hold" rating on shares of Denali Therapeutics in a research report on Monday, June 22nd. Finally, JPMorgan Chase & Co. assumed coverage on Denali Therapeutics in a report on Monday, July 13th. They set an "overweight" rating and a $29.00 target price on the stock. Thirteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $35.92.

Denali Therapeutics Stock Up 0.7%

Shares of NASDAQ DNLI opened at $25.00 on Tuesday. The company has a current ratio of 8.37, a quick ratio of 8.32 and a debt-to-equity ratio of 0.01. Denali Therapeutics has a 12 month low of $12.58 and a 12 month high of $27.30. The firm has a market capitalization of $3.97 billion, a PE ratio of -8.80 and a beta of 1.01. The firm has a fifty day simple moving average of $23.63 and a two-hundred day simple moving average of $21.35.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.17). The company had revenue of $3.60 million during the quarter, compared to the consensus estimate of $2.15 million. During the same period in the previous year, the company posted ($0.72) EPS.

Institutional Investors Weigh In On Denali Therapeutics

Hedge funds have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Denali Therapeutics by 4.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,507 shares of the company's stock worth $1,210,000 after buying an additional 3,432 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Denali Therapeutics by 58.1% during the first quarter. Goldman Sachs Group Inc. now owns 1,672,078 shares of the company's stock valued at $22,732,000 after buying an additional 614,555 shares during the last quarter. Empowered Funds LLC boosted its holdings in Denali Therapeutics by 11.0% in the first quarter. Empowered Funds LLC now owns 20,639 shares of the company's stock worth $281,000 after acquiring an additional 2,052 shares in the last quarter. Woodline Partners LP boosted its holdings in Denali Therapeutics by 13.5% in the first quarter. Woodline Partners LP now owns 113,517 shares of the company's stock worth $1,543,000 after acquiring an additional 13,517 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of Denali Therapeutics by 1.7% in the second quarter. JPMorgan Chase & Co. now owns 191,613 shares of the company's stock worth $2,681,000 after acquiring an additional 3,210 shares during the last quarter. Institutional investors own 92.92% of the company's stock.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company's research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali's approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali's lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson's disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer's patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source